TickerFacts.

Idexx Laboratories Inc (IDXX): Capital Expenditures

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2011-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$124.68M
Year ended 2025-12-31
$117.18M
Trailing 12 months to 2026-06-30
-5.7%
3-year compound annual growth
+3.1%
5-year compound annual growth
+4.2%
10-year compound annual growth
$154.97M2008-12-31: $89.97M2009-12-31: $50.66M2010-12-31: $38.91M2011-12-31: $49.68M2012-12-31: $57.62M2013-12-31: $77.61M2014-12-31: $60.52M2015-12-31: $82.92M2016-12-31: $64.79M2017-12-31: $74.38M2018-12-31: $115.75M2019-12-31: $154.97M2020-12-31: $106.96M2021-12-31: $119.55M2022-12-31: $148.84M2023-12-31: $133.63M2024-12-31: $120.92M2025-12-31: $124.68M$124.68M
2008-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$124.68M+3.1%2026-02-20, From 2025-01-01
2024-12-31$120.92M-9.5%2026-02-20, From 2024-01-01
2023-12-31$133.63M-10.2%2026-02-20, From 2023-01-01
2022-12-31$148.84M+24.5%2025-02-21, From 2022-01-01
2021-12-31$119.55M+11.8%2024-02-22, From 2021-01-01
2020-12-31$106.96M-31.0%2023-02-16, From 2020-01-01
2019-12-31$154.97M+33.9%2022-02-16, From 2019-01-01
2018-12-31$115.75M+55.6%2021-02-12, From 2018-01-01
2017-12-31$74.38M+14.8%2020-02-14, From 2017-01-01
2016-12-31$64.79M-21.9%2019-02-15, From 2016-01-01
2015-12-31$82.92M+37.0%2018-02-16, From 2015-01-01
2014-12-31$60.52M-22.0%2017-02-17, From 2014-01-01
2013-12-31$77.61M+34.7%2016-02-17, From 2013-01-01
2012-12-31$57.62M+16.0%2015-02-17, From 2012-01-01
2011-12-31$49.68Mn/c2014-02-18, From 2011-01-01
2010-12-31$38.91M-23.2%2013-02-19, From 2010-01-01
2009-12-31$50.66M-43.7%2012-02-17, From 2009-01-01
2008-12-31$89.97Mn/a2011-02-22, From 2008-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Idexx Laboratories Inc (IDXX)2025-12-31$124.68M+3.1%
QuidelOrtho Corp (QDEL)2025-12-28$188.20M-3.5%
Neogen Corp (NEOG)2026-05-31$51.30M-51.0%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$1.13M-80.5%
Alpha Teknova, Inc. (TKNO)2025-12-31$1.15M+2.0%
Immucell Corp (ICCC)2025-12-31$1.25M+168.5%
Aspira Women's Health Inc. (AWHL)2025-12-31$16.0K-56.8%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$3.19M+517.2%
Volitionrx Ltd (VNRX)2025-12-31$89.6K-67.7%

Compare IDXX, QDEL, NEOG, NTLA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗